A number of biosimilar drugs are emerging in Canada. As these drugs cannot be considered direct replacements for the innovator biologics they are based on, their adoption in clinical practice is not straightforward. Public payers and regulators can help manage the use of biosimilars by providing guidance and policies on matters of interchangeability, substitutability, prescribing (tiering, switching), pricing, and tendering. This Environmental Scan will provide examples of international post-market policies, programs, and other strategies that have been established to guide the uptake of biosimilars and to promote their appropriate and cost-effective use.
antineoplastic agents, biologics, biosimilar pharmaceuticals, cancer, medical oncology, neoplasms, Biologic, Biological, bio-pharmaceutical, bio-therapeutic, biopharmaceutical, biosimilar, biosimilars, biotherapeutic